New York City, NY (PRWEB) November 06, 2012
On November 6, Voices Against Brain Cancer (VABC) releases a statement lauding the work of Julie Kang, MD with her study of radiation treatment for cancer stem cells, as presented at the annual meeting of the American Society of Radiation Oncology.
According to MedPageToday, the study determined that those who underwent the most aggressive form of the treatment (designated as at least 60 Gray to the ipsilateral hippocampus) had a median survival rate of 20.7 months, whereas those who received a lesser treatment had a median survival period of 15.3 months, an improvement of 5.4 months.
“An extra five and a half months may not seem like a lot,” notes Clay Darrohn, VABC representative. “But, if there was a treatment out there that could give you five more months to spend with your loved ones, wouldn’t you consider it to be an amazing step forward?”
MedPageToday noted that the study was just the first of many and that many more would be needed in order to ensure that this treatment can be used in order to help all patients who suffer from glioblastoma.
“Like all medical research, when it comes to finding a cure for brain cancer, we have a long way to go,” states Darrohn. “But everything—no matter how big or how small—deserves praise when it comes to this. VABC lauds Kang’s work and the work of her peers. Every step we take toward a world without brain cancer is a step worth taking.”
VABC has a wide variety of initiatives in place for brain cancer research, awareness and support. The organization’s research grants fund cutting-edge research programs that will have a monumental impact on the diagnosis and treatment of brain cancer. VABC currently funds research at several esteemed institutions such as Brookhaven National Laboratory, Cleveland Clinic, Columbia, Cornell, Duke, Harvard, John Hopkins, Memorial Sloan-Kettering and Yale, to name a few.
VABC's mission is to find a cure for brain cancer by advancing scientific research, increasing awareness within the medical community and supporting patients, their families and caregivers afflicted with this devastating disease.
For press inquiries, please contact: 5W Public Relations.